MONALEESA-2: Ribociclib + Letrozole — Mobile Quick Reference

Save for clinic

📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications

🎯 Clinical Bottom Line

MONALEESA-2 showed that adding ribociclib to letrozole as first-line therapy for postmenopausal women with HR-positive, HER2-negative metastatic breast cancer significantly improved overall survival — the only first-line CDK4/6 inhibitor trial in this population to achieve a statistically significant OS result. This solidifies ribociclib + aromatase inhibitor as a preferred first-line standard of care.

Key Result: Overall survival — 63.9 vs 51.4 months, HR 0.76 (95% CI 0.63–0.93; two-sided P=0.008)

Safety Signal: Grade 3 or 4 neutropenia occurred in 63.8% of ribociclib-treated patients — requires routine CBC monitoring and established dose modification protocols.

✅ Patient Eligibility

Must Have:

• HR-positive, HER2-negative breast cancer
• Recurrent or metastatic disease — first-line setting
• Postmenopausal status
• ECOG PS 0–1
• Measurable disease (RECIST v1.1) or at least one predominantly lytic bone lesion

Cannot Have:

• Prior CDK4/6 inhibitor therapy
• Prior systemic endocrine therapy or chemotherapy for advanced disease
• Prior adjuvant NSAI unless disease-free interval >12 months

💊 Dosing Quick Guide

Experimental Regimen

Ribociclib: 600 mg orally once daily, Days 1–21 Letrozole: 2.5 mg orally once daily, continuous Cycle: 28 days (3 weeks on / 1 week off for ribociclib) Duration: Until disease progression or unacceptable toxicity

Control Regimen

Placebo: Matching placebo on same schedule as ribociclib Letrozole: 2.5 mg orally once daily, continuous

Key Dose Modifications [2]

• Dose reduction levels: 600 mg → 400 mg → 200 mg
• Neutropenia: Hold for Grade 3; resume at same or reduced dose when ≤Grade 2. Hold for Grade 4; resume at next lower dose when ≤Grade 2
• Monitoring: CBC every 2 weeks × 2 cycles, then every 4 cycles. ECG at baseline, Day 14 of Cycle 1, beginning of Cycle 2. LFTs on same schedule as CBC.

Mechanism: Ribociclib is a selective CDK4/6 inhibitor that blocks retinoblastoma protein phosphorylation, arresting tumor cell cycle progression from G1 to S phase [2].

⚠️ Safety Snapshot

⚠️ Neutropenia: Grade 3 or 4 in 63.8% of ribociclib-treated patients. Requires routine CBC monitoring and dose modification per label.

⚠️ ILD/Pneumonitis: Grade 3 in 0.6% (2 patients) of ribociclib group; no grade 4 or fatal events.

Key safety metrics:

• On-treatment deaths: 8 of 334 (ribociclib) vs 3 of 330 (placebo)

📊 Key Numbers

Median follow-up: 80 months (minimum, 75 months)

🔬 Key Comparator Context

Cross-trial comparisons are limited by differences in populations, designs, and endpoints.

🔍 Subgroups to Watch

Newly diagnosed metastatic disease: HR 0.52 (95% CI 0.36–0.74) — pronounced benefit vs recurrent disease (HR 0.91) Age <65 yr: HR 0.69 (95% CI 0.53–0.90) — numerically greater benefit than age ≥65 (HR 0.87) ≥3 metastatic sites: HR 0.71 (95% CI 0.51–0.98) — benefit maintained in higher disease burden Other HR status (not ER+/PgR+): HR 0.58 (95% CI 0.37–0.89) — numerically greater benefit than ER+/PgR+ (HR 0.82)

Subgroup analyses were exploratory and not powered for formal comparisons. Results are hypothesis-generating.

📋 Regulatory Status

⚠️ Verify current regulatory status before prescribing.

NCCN: CDK4/6 inhibitor + AI is a preferred first-line regimen for HR+/HER2− metastatic breast cancer, Category 1 [3]

⚡ Grey Zones

• Only postmenopausal women enrolled — no direct evidence for premenopausal patients from this trial
• Only 2.5% of patients were Black — limited generalizability to underrepresented populations
• No head-to-head comparison with palbociclib or abemaciclib — cannot confirm CDK4/6 inhibitor superiority
• Patients with prior adjuvant CDK4/6 inhibitor exposure were excluded — growing population unaddressed
• Optimal post-progression sequencing after first-line ribociclib remains undefined

📖 Full Analysis

Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.

References

1. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386:942-950. doi:10.1056/NEJMoa2114663
2. Kisqali (ribociclib) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
4. Finn RS, Rugo HS, Diéras V, et al. Overall Survival with First-Line Palbociclib plus Letrozole versus Placebo plus Letrozole in Women with ER+/HER2− Advanced Breast Cancer: Analyses from PALOMA-2. Ann Oncol. 2022;33(10):1068-1078. doi:10.1016/j.annonc.2022.07.1940
5. Goetz MP, Toi M, Huober J, et al. MONARCH 3: Abemaciclib as Initial Therapy for Patients with HR+/HER2− Advanced Breast Cancer — Final Overall Survival Results. J Clin Oncol. 2024;42(8):860-869. doi:10.1200/JCO.23.01000